Prostatic disease and sexual dysfunction

Korean Journal of Urology

Volumn 52, Issue 6, 2011, Pages 373-378

  Kim, Sae Woong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Erectile dysfunction; Prostatic hyperplasia; Prostatic neoplasms; Prostatitis

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANDROSTANOLONE; CIPROFLOXACIN; DOPAMINE RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NITRIC OXIDE; SEROTONIN RECEPTOR;

ACUTE BACTERIAL PROSTATITIS; AGE; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ANTIBIOTIC SENSITIVITY; CARDIOVASCULAR DISEASE; CHRONIC BACTERIAL PROSTATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PROSTATITIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EJACULATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INFERTILITY; INFLAMMATORY PROSTATITIS; LIFESTYLE; LOWER URINARY TRACT SYMPTOM; LUNG DISEASE; MENTAL STRESS; MULTICENTER STUDY (TOPIC); POSTOPERATIVE COMPLICATION; PREMATURE EJACULATION; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; QUALITY OF LIFE; RADIOTHERAPY; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SMOKING; SMOOTH MUSCLE TONE; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 79959859588     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.6.373     Document Type: Review

References (58)

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91.
2. Yong DJ, Lee KC, Cho IR. The effect of lower urinary tract symptoms on erectile function and the frequency of sexual intercourse. Korean J Urol 2007;48:458-62.
3. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical Aging Male symptoms? Results of the Cologne Male Survey. Eur Urol 2003;44:588-94.
4. Chung WS, Nehra A, Jacobson DJ, Roberts RO, Rhodes T, Girman CJ, et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc 2004;79:745-9.
5. Cha JS, Park JK. Association between lower urinary tract symptoms and erectile dysfunction. Korean J Urol 2005;46:1023-7.
6. Burger B, Weidner W, Altwein JE. Prostate and sexuality: an overview. Eur Urol 1999;35:177-84.
7. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-8.
8. Wiygul RD. Prostatitis: epidemiology of inflammation. Curr Urol Rep 2005;6:282-9.
9. Krieger JN. Classification, epidemiology, and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol 2004;56:99-107.
10. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004;93:568-70.
11. Lutz MC, Roberts RO, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Cross-sectional associations of urogenital pain and sexual function in a community based cohort of older men: Olmsted county, Minnesota. J Urol 2005;174:624-8.
12. Brown AJ. Ciprofloxacin as cure of premature ejaculation. J Sex Marital Ther 2000;26:351-2.
13. El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med 2007;4:491-6.
14. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-9.
15. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
16. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez- Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001;166:569-74.
17. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 2003;92:719-25.
18. Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, et al. Erectile and ejaculatory dysfunction in a community- based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001;57:763-8.
19. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
20. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002;19:390-6.
21. Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al. Pharmacological characterization of isolated human prostate. J Urol 2003;170:1032-8.
22. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995;45:435-9.
23. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995;45:440-6.
24. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003;170:S6- 13.
25. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002;99:4061-6.
26. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546-51.
27. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161: 635-40.
28. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
29. Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha- adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997;18:26-31.
30. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80: 629-38.
31. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170:2517-22.
32. Büyükafşar K, Levent A, Ark M. Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br J Pharmacol 2003;140:743-9.
33. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001;7: 119-22.
34. Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJ, Mills TM, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002;298:427-32.
35. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
36. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Lüscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 1997;30:817-24.
37. Cho JJ, Cadet P, Salamon E, Mantione K, Stefano GB. The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men. Med Sci Monit 2003;9:RA63-8.
38. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8.
39. Burnett AL, Calvin DC, Chamness SL, Liu JX, Nelson RJ, Klein SL, et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med 1997;3:571-4.
40. Mevorach RA, Bogaert GA, Kogan BA. Role of nitric oxide in fetal lower urinary tract function. J Urol 1994;152:510-4.
41. Persson K, Igawa Y, Mattiasson A, Andersson KE. Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 1992;107: 178-84.
42. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 1999;140:1481-91.
43. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function--the most important disease- specific distress for patients with prostate cancer. Br J Cancer 1996;73:1417-21.
44. Karakiewicz PI, Aprikian AG, Bazinet M, Elhilali MM. Patient attitudes regarding treatment-related erectile dysfunction at time of early detection of prostate cancer. Urology 1997;50:704-9.
45. Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy-- myth or reality? J Urol 2008;179:827-31.
46. Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol 2007;51:1229-35.
47. Müller A, Parker M, Waters BW, Flanigan RC, Mulhall JP. Penile rehabilitation following radical prostatectomy: predicting success. J Sex Med 2009;6:2806-12.
48. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164:1929-34.
49. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int 2008; 101:833-6.
50. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172:2227-31.
51. Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol 2008;179:2207-10.
52. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004;45:123- 33.
53. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53: 68-80.
54. Namiki S, Ishidoya S, Tochigi T, Ito A, Arai Y. Quality of life after radical prostatectomy in elderly men. Int J Urol 2009;16:813-9.
55. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen- detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000;48:629-33.
56. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Crit Rev Oncol Hematol 2006; 57:165-73.
57. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250- 61.
58. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol 2007;14:416-21.